Business Wire

BRYAN-GARNIER-&-CO

Share
Europe's Software Vendors Highly Valued in US Comparison

European investment bank Bryan, Garnier & Co today presented a study that clearly refutes the widespread structural undervaluation of European software vendors. When the usual EV/sales multiples (enterprise value / expected sales for the next year) are related to the average expected growth over three years (CAGR), European software vendors are even trading at a valuation premium of around nine percent (eight percent in the case of SaaS providers) compared to their US competitors.

For this analysis, software analyst Gregory Ramirez compared the valuations of all 95 European-listed and 97 US-listed software vendors between 2006 and 2020, for which there is historical analyst consensus data from Refinitiv. These companies include 29 European and 67 US SaaS vendors.

A superficial look at the simple sales multiples shows that the US providers' multiple of 9.9 over the last 15 years is significantly higher than the 5.6 of their European competitors. However, if the stock market value is not only assessed on the basis of the simple sales multiple, but average growth1 is taken into account and both are placed in relation to each other, a completely different picture emerges. This puts the significance of the sales expectation for the next year into perspective.

For example: if in April 2021 Salesforce shares were trading at a revenue multiple of 10 (10x expected revenue in 2022) and the expected average revenue growth (CAGR) for 2020-2023 is 20%, the ratio is 10 / 0.2 / 100 and the newly calculated ratio is 0.50. The analyst did this calculation for the 15 years up to April 2021 and came up with a surprising result, which is that the valuations of software companies on the European stock exchanges are not only on par with the companies listed in the US, they are slightly higher. For the Europeans, this results in an average valuation that is nine percent higher than that of their US competitors. The same principle applied to the 29 or 67 (US) listed SaaS providers over a four-year period yields almost the same result: here, the average premium is eight percent.

Ramirez explains: "This picture is much closer to the reality of the stock market valuation. This weighting with the average growth rate normalizes the multiples and thus relativises the significance of the short-term growth expectation for a single year.”

The study also shows that the differences in the individual valuations of software providers listed in Europe are wider than those of their US competitors. This dispersion cannot be explained by a significant number of loss-making companies among European software vendors, nor by the liquidity of their shares. Contrary to another common prejudice, the most highly valued European software stocks are by no means always the most liquid, nor are they necessarily listed on the most liquid markets.

Valuation is not decided by the stock market

Bryan, Garnier & Co explain that the heterogeneity of the valuation of European software providers is a result of very different business models, track records and corporate governance. Above all, the degree of maturity of the European companies is very different, while US companies almost always have a long maturation process with numerous financing rounds behind them before going public.

"This makes it clear that the stock exchange location is not decisive for the valuation of a software company. It's all about the quality of the business model and management, the degree of maturity and the track record to date ," explains Greg Revenu, Managing Partner of Bryan, Garnier & Co. This is an important insight, he says, "because for Europeans an IPO in the USA is usually associated with many difficulties .” Pierre Kiecolt-Wahl, Partner and Head of ECM at Bryan, Garnier & Co adds: "If the stock market success of European software companies is ultimately independent of the chosen stock exchange, there is not the slightest argument against an IPO on a European stock exchange. "

WEBINAR:

Debunking the software valuation gap: European software companies going public in the US
Bryan, Garnier & Co will be hosting a webinar on Thursday 27 May , 10h CET – 10h45 to discuss the report findings in more detail. Join us >>

About Bryan, Garnier & Co (www.bryangarnier.com )

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.

1 CAGR - in this case a three-year moving average of the expected growth rates of the current year and the next two years

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release

Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management

Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release

Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc

Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse

Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye